Inclusion Criteria:

1. Subjects either with a histological confirmed diagnosis of prostate cancer or a history of previous prostate cancer specific treatment destined to initiate hormonal and/or chemotherapy treatments.
   1. This includes prostate cancer subjects with evidence of clinically biochemically progressive disease post surgical or radiation treatments for localized stage disease as deemed by the treating physician or after failure of androgen deprivation therapy. Biochemical evidence of progressive disease is defined as either as a serially rising PSA for two consecutive measurements, at least four weeks apart and clinical evidence for progression is defined as development of grossly metastatic disease as evidenced on clinical imaging scans performed as part of standard clinical care prior to enrollment.
2. Age: 18 to 100 years
3. Subject must be able to sign an informed consent.
   1. Informed consent must be signed at the time of enrollment and/or collection of any specimen and/or clinical data (other than PHI needed to screen and identify patients, which will be promptly discarded in a secure fashion if patient is not enrolled on study).

Exclusion Criteria:

1. Subjects either incarcerated or with limited decision making capacity;
2. Subjects clinically judged to be at increased risk of bleeding from phlebotomy;
3. Subjects with hemoglobin  ≤7gm%.
4. Subjects with a previous history of known second non-GU malignancy in the past five years.